New evidence-based guideline for HPV testing in head and neck cancers.
It is now well established that a subset of head and neck carcinomas is defined by their association with high-risk types of human papillomavirus (HPV). These HPV-driven head and neck carcinomas are characterized by distinct histologic and clinical features, including an excellent prognosis and response to therapy. Although the recognition of this subtype of head and neck cancer has been a significant advancement in head and neck oncology, confusion has persisted regarding why, when, and how HPV testing should be carried out. The College of American Pathologists (CAP) recently published evidence-based guidelines addressing HPV testing in head and neck carcinomas, offering much-needed clarification on a complicated issue. This review will detail each CAP guideline while also explaining the rationale and methods for their creation.